DP13: Our Investigational Drug
An aldosterone synthase inhibitor, DP13 is a first-of-its-kind treatment for PA that medically targets the cause of the disease. DAMIAN successfully completed its Phase I Clinical Trial evaluating the pharmacological properties of DP13 in healthy volunteers. The safety and efficacy of DP13 is currently being investigated across Europe in patients with PA in a Phase II Trial.
Currently available therapies have no impact on the cause of PA i.e., the overproduction of aldosterone. In contrast, DP13 selectively inhibits the enzyme responsible for aldosterone production, thus directly reducing the amount of aldosterone in the body.